Uroplasty, Inc. to Present at the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics & Metabolic Disorders Medical Device Conference

MINNEAPOLIS, Nov. 30, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, announced today that David Kaysen, President and CEO, and Medi Jiwani, Vice President and CFO, will present the Company’s business strategy and financial results at the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics & Metabolic Disorders Medical Device Conference at 4:00 PM PT on Tuesday, December 6, 2011 at The St. Regis Hotel in San Francisco.

Attendance at the conference is by invitation only. A live audio webcast of the presentation will be broadcast via the Internet. Those interested in listening to the webcast may access it at http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=3742860, or through Uroplasty’s website at www.uroplasty.com. An archived replay of the presentation will be available for 90 days.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

SOURCE Uroplasty, Inc.